CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

WESTON, Fla., May 20, 2024 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U….

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks